What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment
Open Access
- 28 September 2015
- journal article
- review article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (34) , 35589-35601
Abstract
The RAS-related signalling cascade has a fundamental role in cell. It activates differentiation and survival. It is particularly important one of its molecules, B-RAF. B-RAF has been a central point for research, especially in melanoma. Indeed, it lacked effective therapeutic weapons since the early years of its study. Molecules targeting B-RAF have been developed. Nowadays, two classes of molecules are approved by FDA. Multi-target molecules, such as Sorafenib and Regorafenib, and selective molecules, such as Vemurafenib and Dabrafenib. Many other molecules are still under investigation. Most of them are studied in phase 1 trials. Clinical studies correlate B-RAF inhibitors and QT prolongation. Though this cardiovascular side effect is not common using these drugs, it must be noticed early and recognize its signals. Indeed, Oncologists and Cardiologists should work in cooperation to prevent lethal events, such as fatal arrhythmias or sudden cardiac death. These events could originate from an uncontrolled QT prolongation.Keywords
This publication has 93 references indexed in Scilit:
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 MutationsNew England Journal of Medicine, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationNew England Journal of Medicine, 2011
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancerCancer Chemotherapy and Pharmacology, 2010
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survivalThe EMBO Journal, 2010
- PKA phosphorylation of HERG protein regulates the rate of channel synthesisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Mutations of the BRAF gene in human cancerNature, 2002